

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 00-1282)

PATENT


In the Application of:

Jourdier et al.

Serial No.: 09/720,513

Filing Date: March 26, 2001

For: Mucosal Targeting Immunisation



Examiner: Bao Q. Li

Group Art Unit: 1648

Confirmation No.: 3546

#7
IDS
Wallace
6/24/02

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Pursuant to 37 C.F.R. §1.98(d), copies of references numbered 1-11 are not provided herewith, since they were previously provided by the IB to the USPTO as an Elected Office as noted in PTO Form 905, "Notification of Missing Requirements" in relation to application no. PCT/FR98/08353, of which the present application is a U.S. national phase.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

U. S. PATENTS

1. Sarkisov et al., U.S. Patent No. 4,368,191, issued January 11, 1983.
2. Letchworth et al., U.S. Patent No. 5,462,734, issued October 31, 1995.
3. Gaffar et al., U.S. Patent No. 3,931,398, issued January 6, 1976.

CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, Washington D.C. 20231 on May 28, 2002.

Date: May 28, 2002

06/17/2002 NMDHAMH1 00000104 09720513

01 FC:126

180.00 DP

Michael S. Greenfield

FOREIGN PATENT DOCUMENTS

4. French Patent No. 2 751 879, published February 6, 1998.

OTHER DOCUMENTS


5. Jian-Ming et al. "Immunogenic potential of rgp120 from African HIV-1 subtype A". *Vaccine*. Vol. 14, No. 10. pp. 993-1000 (July 1996).
6. Kim et al. "Development of a multicomponent candidate vaccine for HIV-1." *Vaccine*. Vol. 15, No. 8. pp. 879-883 (June 1997).
7. Anderson et al. "Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 12 of HIV-1." *J. Infect. Dis.* Vol. 160, No. 6 pp. 960-969 (1989).
8. Davis et al. "A recombinant prime peptide boost vaccination strategy can focus the immune response on to more than one epitope even though these may not be immunodominant in the complex immunogen." *Vaccine*. Vol. 15, No. 15, pp. 1661-1669 (October 1997).
9. Sasaki et al. "Induction of systemic and mucosal immune response to human immunodeficiency virus type 1 by a DNA vaccine formulated with OS-21 saponin adjuvant via intramuscular and intranasal routes." *Journal of Virology*. pp. 4931-9 (June 1998).
10. Russell et al. "Induction of the mucosal immune response." *Rev. Infect. Dis.* Vol. 10, No. Suppl. 2, pp. s440-s446 (1988).
11. Thibodeau et al. "Oral priming followed by parenteral immunization with HIV-immunosomes induce HIV-1-specific salivary and circulatory IgA in mice and rabbits." *AIDS Research and Human Retroviruses*. Vol. 8, No. 8, pg. 1379 (1992).

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Date: May 28, 2002

By:


Michael S. Greenfield
Reg. No. 37,142